|
|
|
|
CancerEducation: Multiple Myeloma Update from the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
|
|
|
|
Multiple myeloma is a hematologic malignancy that affects tens of thousands of people annually. For decades, there had been limited therapeutic advancements for myeloma patients as the understanding of this disease slowly increased. In more recent years, because of the discovery of some of the molecular pathways of the disease, new therapies have been successful in clinical studies for treating both relapsed/refractory diseases in myeloma patients as well as newly diagnosed patients. In addition, increased attention and study has been focused on improving the efficacy and tolerability of transplantation.
|
|
|
|
This activity has been designed to meet the educational needs of healthcare professionals involved in the care of patients with multiple myeloma. |
|
|
|
Upon completion of this activity, the participants will be able to:
- Review clinical advances in the treatment of patients newly diagnosed with multiple myeloma.
- Describe the role of novel targeted therapies for treating patients with relapsed and refractory multiple myeloma.
- Review the side effect profiles of new myeloma therapies and their resolution.
|
|
|
|
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine, AOI Communications, L.P., and the Multiple Myeloma Research Foundation. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians. |
|
|
|
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
|
|
|
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest or a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter |
Reported Financial Relationship |
Jean-Paul Fermand, MD |
No financial interest/relationship with financial interests relating to the topic of this activity
|
Carol Ann Huff, MD
|
Consulting fees: Celgene Corporation, Millennium Pharmaceuticals, Inc. |
S. Vincent Rajkumar, MD |
Grants/Research: Celgene Corporation, Millennium Pharmaceuticals, Inc. |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager |
Reported Financial Relationship |
Tom Burke (AOIC) |
No financial interest/relationships with financial interests relating to the topic of this activity
|
Mary Dominiecki, PhD (AOIC)
|
No financial interest/relationships with financial interests relating to the topic of this activity
|
Anne Quinn Young, MPH (MMRF) |
No financial interest/relationships with financial interests relating to the topic of this activity |
Jan Hixon, RN, BSN, MA (PIM)
|
No financial interest/relationships with financial interests relating to the topic of this activity |
|
|
|
|
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine (PIM), the Multiple Myeloma Research Foundation, AOI Communications, L.P., Celgene Corporation, and Millennium Pharmaceuticals, Inc., do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, the Multiple Myeloma Research Foundation, AOI Communications, L.P., Celgene Corporation, and Millennium Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. |
|
|
|
There are no fees for participating and receiving CME credit for this activity. During the period June 2008 through June 2009, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the posttest by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) the Postgraduate Institute for Medicine will mail your certification of completion.Media
Internet |
|
|
|
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. |
Click to Continue
|
|
|
|
|
|
|
Jean-Paul Fermand, MD
